Headache News and Research

Latest Headache News and Research

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Painkiller combinations cost more but are less effective: Report

In a new article in the journal Australian Prescriber, there is a warning that combination painkillers cause more side effects and may not provide the relief promised. This comes from the National Prescribing Service (NPS), Australia's medicine review body.

1 Aug 2010

Stop & Shop Supermarket announces voluntary recall of Nature's Promise Alfalfa, Zesty Sprouts

The Stop & Shop Supermarket Company has announced a voluntary recall of Nature's Promise Alfalfa and Zesty Sprouts because they have the potential to be contaminated with listeria monocytogenes.

31 Jul 2010

Sanofi Pasteur announces shipping of Fluzone Influenza Virus Vaccine in the U.S.

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that shipping of the 2010-2011 formulation of its seasonal influenza vaccine Fluzone Influenza Virus Vaccine is underway in the U.S.

31 Jul 2010

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

GlaxoSmithKline announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution of Fluarix® [Influenza Virus Vaccine] to follow in the next several weeks.

30 Jul 2010

Orexigen's Contrave COR-I trial results published online in journal Lancet

Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

30 Jul 2010

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Pretreating polycarbonate plastic is an eco-friendly way of waste disposal: Research

Just as cooking helps people digest food, pretreating polycarbonate plastic - source of a huge environmental headache because of its bisphenol A (BPA) content - may be the key to disposing of the waste in an eco-friendly way, scientists have found. Their new study is in ACS' Biomacromolecules, a monthly journal.

29 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Dengue fever emerges as major health threat in Gulf coast cities

Several cases of dengue fever, a potentially fatal viral disease transmitted by the bite of urban dwelling Aedes aegypti and Aedes albopictus mosquitoes, have recently been reported in the continental United States. Prevalent in Central America and the Caribbean, dengue fever's most common symptoms include fever, chills, headache, and body aches lasting several days. The disease's more threatening form, dengue hemorrhagic fever, can cause internal bleeding, loss of blood pressure, and death. Over the past five years, outbreaks of both forms of the disease have been reported in Texas and Florida.

28 Jul 2010

Novartis launches new OTC children's liquid acetaminophen product

Novartis announces the introduction of Triaminic™ Fever Reducer Pain Reliever, the only branded over-the-counter children's liquid acetaminophen product currently available nationwide in the US. Triaminic® now offers parents a product that combines the pain relieving and fever-reducing power of acetaminophen with the brand that has been trusted by pediatricians and parents for more than 50 years.

27 Jul 2010

Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability -- a core symptom of fragile X syndrome.

26 Jul 2010

Babesiosis disease on the rise in Lower Hudson Valley: NYS DOH

Babesiosis, a rare and occasionally fatal tick-borne disease caused by microscopic parasites known as Babesia which infect red blood cells, is on the rise in the Lower Hudson Valley according to the NYS DOH, including the counties of Westchester, Putnam, Orange, Dutchess, Ulster, Sullivan and Rockland.

23 Jul 2010

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.

23 Jul 2010

Three toxins in food identified as triggers to gluten intolerance: study

Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.

22 Jul 2010

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

Headache News and Research

Latest Headache News and Research

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Painkiller combinations cost more but are less effective: Report

Stop & Shop Supermarket announces voluntary recall of Nature's Promise Alfalfa, Zesty Sprouts

Sanofi Pasteur announces shipping of Fluzone Influenza Virus Vaccine in the U.S.

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

Orexigen's Contrave COR-I trial results published online in journal Lancet

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Pretreating polycarbonate plastic is an eco-friendly way of waste disposal: Research

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Dengue fever emerges as major health threat in Gulf coast cities

Novartis launches new OTC children's liquid acetaminophen product

Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome

Babesiosis disease on the rise in Lower Hudson Valley: NYS DOH

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

Three toxins in food identified as triggers to gluten intolerance: study

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Genentech disappointed with FDA ODAC's recommendation against Avastin

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in